Results 61 to 70 of about 1,343 (129)

UEG Week 2025 Poster Presentations

United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley   +1 more source

Rebamipide Prevents the Hemoglobin Drop Related to Mucosal-Damaging Agents at a Level Comparable to Proton Pump Inhibitors

Gut and Liver
Background/Aims: The effect of proton pump inhibitors (PPIs) on the lower gastrointestinal (GI) tract is uncertain, with potential to worsen damage. This study aimed to find the best method for protecting the entire GI tract from mucosal damage. Methods:
Ji Eun Kim, Yeong Chan Lee, Tae Se Kim, Eun Ran Kim, Sung Noh Hong, Young-Ho Kim, Kyunga Kim, Dong Kyung Chang   +7 more
doaj   +1 more source

Rebamipide gargle and benzydamine gargle in prevention and management of chemo-radiotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients (randomized clinical trial)

BMC Oral Health
Objectives This study aimed to evaluate the preventive and therapeutic effects of rebamipide gargle in comparison with benzydamine in head and neck cancer patients undergoing radiotherapy with or without chemotherapy.
Basma Elsaadany, Samah M. Anayb, Karim Mashhour, Mohammed Yossif, Fat’heya Zahran   +4 more
doaj   +1 more source

The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract [PDF]

Терапевтический архив, 2016
Rebamipide is a cytoprotесtive drug that stimulates the generation of endogenous prostaglandins in the gastric and small intestinal mucosa and accelerates the healing of erosions and ulcers caused by Helicobacter pylori infection and NSAID administration.
E P Yakovenko, N A Agafonova, A N Ivanov, A V Yakovenko, M A Aldiyarova, T V Volosheinikova, Yu V Grigoryeva, I P Soluyanova   +7 more
doaj  

Topical rebamipide improves the ocular surface in mild lagophthalmos

Clinical Ophthalmology, 2013
Mariko Itakura,1 Hirotaka Itakura,1,2 Tomoyuki Kashima,2 Hideo Akiyama,2 Shoji Kishi21Department of Ophthalmology, Maebashi Red Cross Hospital, Maebashi, Japan; 2Department of Ophthalmology, Gunma University, School of Medicine, Maebashi, JapanAbstract ...
Itakura M, Itakura H, Kashima T, Akiyama H, Kishi S   +4 more
doaj  

Efficacy of Rebamipide (Coxipide) in Treating Dry Eye and Dry Mouth in Sjögren’s Syndrome: A Randomized Controlled Trial

Journal of Clinical Rheumatology and Immunology
Background: Sjögren’s syndrome (SS) is a chronic autoimmune disorder that primarily affects the lacrimal and salivary glands, resulting in dry eye (xerophthalmia) and dry mouth (xerostomia), both of which can significantly impair quality of life ...
Asif Islam, Fatima Khurshid, Zainab Younus, Umar Haider, Kinza Randhawa, Rimsha Rameen   +5 more
doaj   +1 more source

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal

Clinical Ophthalmology, 2014
Tomoyuki Kashima,1 Hirotaka Itakura,1,2 Hideo Akiyama,1 Shoji Kishi11Department of Ophthalmology, Gunma University, School of Medicine, Maebashi, Gunma, Japan; 2Department of Ophthalmology, Maebashi Red Cross Hospital, Maebashi, Gunma, JapanAbstract ...
Kashima T, Itakura H, Akiyama H, Kishi S
doaj  

Resolution of persistent corneal erosion after administration of topical rebamipide

Clinical Ophthalmology, 2012
Tomoyuki Kashima,1,2 Hideo Akiyama,1 Fumihide Miura,2 Shoji Kishi11Department of Ophthalmology, Gunma University School of Medicine, Maebashi, Japan; 2Department of Ophthalmology, Saku Central Hospital, Saku, JapanAbstract: Rebamipide is an antiulcer ...
Kashima T, Akiyama H, Miura F, Kishi S
doaj  

Mucin armoured diethylaminoethyl-dextran cloaked rebamipide based oral nanoformulation for the therapy of inflammatory bowel disease. [PDF]

Mater Today Bio
Jori C, Ahmad A, Kumar A, Ali N, Son YO, Khan R.   +5 more
europepmc   +1 more source

Efficacy of rebamipide for the treatment of dry eye disease: An updated meta-analysis of randomized and non-randomized controlled trials. [PDF]

Medicine (Baltimore)
Murtaza M, Farooque U, Batool A, Rasool M, Ahmed N, Hafsa Qadri S, Ali Akbar M, Ali S, Patel T, Patel T.   +9 more
europepmc   +1 more source